Hyperuricemia

Cardiovascular Safety of Febuxostat vs Allopurinol Compared in Patients With Gout

Publish Date June 23, 2021

Researched analyzed the risk for adverse cardiovascular events and death with febuxostat vs allopurinol in patients with gout.

Impact of Uncontrolled Gout on Quality of Life and Importance of Open Dialogue With Patients

Publish Date July 1, 2021

For Arthritis Awareness Month and Gout Awareness Day 2021, Suneet Grewal, MD, provides a deeper insight into the impact of uncontrolled gout on the quality of life of patients and the importance of having an open dialogue.

Study Evaluates Characteristics, Comorbidities, and Kidney Function of Patients With Uncontrolled Gout Receiving Pegloticase

Publish Date June 22, 2021

In this study presented at the EULAR 2021 Virtual Congress, researchers examined the demographics and comorbidities of patients with uncontrolled gout receiving pegloticase.

High, Low Uric Acid Levels Increase Chronic Kidney Disease Risk

Publish Date June 11, 2021

In a study of middle-aged adults, serum uric acid levels less than 4.0 and 10.0 mg/dL or higher in men and less than 4.0 and 8.0 mg/dL or higher in women were significantly associated with increased risks for chronic kidney disease.

Safety and Efficacy Data of Gout Flare Prophylaxis Analyzed in Patients With Chronic Kidney Disease

Publish Date June 2, 2021

The review was aimed at describing the current literature on the efficacy and safety of gout flare prophylaxis and therapy in patients with chronic kidney disease.

Sodium-Glucose Cotransporter-2 Inhibitors Linked to Reduced Risk for Gout

Publish Date June 1, 2021

Researchers studied the association between sodium-glucose cotransporter-2 (SGLT2) inhibitors and gout, using a cohort study design and a symmetry analysis.

Urate Transporter Variants Associated With Transition From Asymptomatic Hyperuricemia to Gout

Publish Date May 11, 2021

Researchers examined the genetic variants associated with the transition from hyperuricemia to gout.

Proinflammatory Cytokines Elevated in Patients With Intercritical Gout, and Linked to MSU Deposition Size and CV Risk Factors

Publish Date April 28, 2021

Researchers studied subclinical inflammation in intercritical gout and its association with the size of monosodium urate crystal deposition and cardiovascular risk factors.

Clinician Q&A: Can Immunomodulators Improve the Effect of Pegloticase in Uncontrolled Gout?

Publish Date April 2, 2021

Robert T. Keenan, MD, discusses the role of co-treatment with immunomodulators and pegloticase in patients with uncontrolled gout.

Gout and Hyperuricemia Have Distinct Serum Metabolomic Signatures

Publish Date April 23, 2021

Researchers studied metabolic alterations and dysregulated metabolic pathways in hyperuricemia and gout, and discovered potential metabolite biomarkers to differentiate between gout and asymptomatic hyperuricemia.